Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Vivaglobin Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?
The expansion observed in the historic period resulted from enhanced diagnosis rates of primary immunodeficiency disorders, greater clinical acceptance of SCIg therapies, the expansion of specialty pharmacy networks, increased availability of plasma-derived therapeutics, and a rising awareness among physicians regarding immune disorders.
The projected growth during the forecast period stems from several factors, including an increasing need for self-administered immunoglobulin treatments, the broadening application of personalized immunotherapy strategies, and greater investment in the development of therapies for rare diseases. Furthermore, the expanding elderly population suffering from immune disorders and continuous improvements in plasma fractionation technologies are significant contributors to this growth.
Notable trends expected throughout the forecast period involve a rising adoption of subcutaneous immunoglobulin therapies, a growing inclination towards administering treatments at home, and an intensified focus on long-term immune replacement solutions. Additionally, the expansion of dosing options centered around patient needs and an increased emphasis on the safety and tolerability of treatments are key developments.
Get A Free Sample Report With In-Depth Market Insights:
Vivaglobin Market Industry Drivers: What’s Behind The Revenue Growth?
The future expansion of the vivaglobin market is significantly influenced by the rising occurrence of primary immunodeficiency diseases (PI). These conditions involve an immune system that is deficient or absent, hindering the body’s defense against infections and increasing susceptibility to various illnesses. The growing prevalence of PI stems from advancements in diagnostic tools, increased public awareness and recognition of these disorders, improved genetic screening, and better identification of cases that were previously undiagnosed. Vivaglobin aids in managing primary immunodeficiency diseases by delivering a consistent supply of antibodies through subcutaneous administration, thereby boosting the immune system’s capacity to fight infections and lessening the frequency and intensity of recurring illnesses in affected individuals. For example, a report from August 2023 by Thermo Fisher, a US-based life science and clinical research company, indicated that an estimated 6 million people globally suffer from PID, with approximately 5,000 individuals in the UK affected by this disorder. Consequently, the increasing prevalence of Primary Immunodeficiency Diseases (PI) is anticipated to fuel the vivaglobin market’s growth. The vivaglobin market is expected to expand with increasing investments in research and development. Medical R&D encompasses the methodical exploration of novel drugs, therapies, or healthcare technologies to advance healthcare, involving clinical studies, laboratory experiments, and regulatory procedures to confirm safety and effectiveness. Heightened R&D in medicine leads to the discovery of innovative treatments, better patient outcomes, and solutions for evolving health challenges. For vivaglobin, increased research and development facilitates advancements in immunoglobulin formulations, optimizes administration techniques, and improves the efficacy and availability of treatment for patients suffering from primary immunodeficiency diseases. As an illustration, The Office for National Statistics (ONS), a UK-based producer of official statistics, reported in April 2025 that the UK government’s net R&D expenditure grew by 8.2% year-on-year, increasing from £16.1 billion in 2022 to £17.4 billion in 2023. Thus, greater investment in research and development is stimulating the growth of the vivaglobin market.
Vivaglobin Market Segment Landscape: Which Areas Lead Development?
The vivaglobin market covered in this report is segmented –
1) By Indication: Primary Immune Deficiency (PID), Secondary Immune Deficiency (SID), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Other Indications
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies
3) By End User: Adult, Geriatric, Pediatric
Vivaglobin Market Industry Leaders And Competitive Landscape
Major companies operating in the vivaglobin market are CSL Behring GmbH
View The Full Vivaglobin Market Report:
Vivaglobin Market Largest Region: Which Geography Holds The Biggest Share?
North America was the largest region in the vivaglobin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vivaglobin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
